President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Hims & Hers (HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk (NVO) announced a partnership with ...

Hims & Hers Health, Inc. teams up with Novo Nordisk to offer Wegovy at $599/month, slashing costs. Click for why this is a ...

Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...

The F.D.A. ordered compounding for versions of Eli Lilly’s Zepbound ... loss products. Some compounders have also sold the drugs in forms that are not permitted by the F.D.A. Image Compounded ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Trump recently proposed tariffs on pharmaceutical products. Experts say this could lead to added costs, drug shortages and even a stall in research and development.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.